RASAGILINE IS AN IRREVERSIBLE SELECTIVE INHIBITOR OF MONOAMINE OXIDASE TYPE B, AN ENZYME INVOLVED IN THE METABOLIC DEGRADATION OF DOPAMINE IN THE BRAIN. IT ENHANCES THE EFFECTS OF LEVODOPA AND IS USED IN THE TREATMENT OF PARKINSON'S DISEASE, EITHER ALONE OR AS AN ADJUNCT TO LEVODOPA THERAPY TO REDUCE 'END-OF-DOSE' FLUCTUATIONS IN RESPONSE.